CHILDREN as young as six will be joining the Oxford University vaccine trials. 

The university wants to check the safety of the vaccine on youngsters and see how successful it is for building immunity to the deadly virus. 

Previous trials have shown that the ChAdOx1 nCoV-19 coronavirus vaccine is safe, produces strong immune system responses and has high efficacy in all adults.

This study, run by the university at sites in London, Southampton and Bristol, will assess if the youngers aged six to 17 make a good immune response. 

The new trial, a single-blind, randomised phase II trial, will enrol 300 volunteers. 

Of these, 240 will get the real vaccine. 

The other 60 will be given another vaccine for meningitis which has been shown to be safe in children but is expected to produce similar reactions - like a sore arm. 

Andrew Pollard, Professor of Paediatric Infection and Immunity, and Chief Investigator on the Oxford vaccine trial, said: "While most children are relatively unaffected by coronavirus and are unlikely to become unwell with the infection, it is important to establish the safety and immune response to the vaccine in children and young people as some children may benefit from vaccination. These new trials will extend our understanding of control of SARS-CoV2 to younger age groups.’

Rinn Song, Paediatrician and Clinician-Scientist, Oxford Vaccine Group, said: "The COVID-19 pandemic has had a profound negative impact on the education, social development and emotional well-being of children and adolescents, beyond illness and rare severe disease presentations. It is therefore important to collect data on the safety and the immune response to our coronavirus vaccine in these age groups, so that they could potentially benefit from inclusion in vaccination programs in the near future.’

Grace Li, Paediatric Clinical Research Fellow, Oxford Vaccine Group, said: "This study will play an important role in helping to protect children in the future. We've already seen that the vaccine is safe and effective in adults, and our understanding of how children are affected by the coronavirus continues to evolve.’

The trial is launched today, and first vaccinations are expected during February. The trial is funded by the National Institute for Health Research (NIHR) and AstraZeneca.

For further information on the trial, including on how to sign up, visit:


Keep up to date with all the latest news on our website, or follow us on Facebook, Twitter and Instagram.

For news updates straight to your inbox, sign up to our newsletter here.

Have you got a story for us? Contact our newsdesk on or 01865 425 445.